We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Phoqus | LSE:PQS | London | Ordinary Share | GB00B0M4CD64 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number : 6322U
Phoqus Pharmaceuticals PLC
16 May 2008
This announcement replaces the Phoqus Pharmaceuticals Annual Report and Accounts announcement released today at 07:00am under RNS number
6089U. The date of the AGM should read Thursday 12 June 2008 and not 2007 as previously stated. All other details remain unchanged. The full
announcement text appears below.
Phoqus Pharmaceuticals plc publishes Annual Report and Accounts for 2007
West Malling, UK, 16 May 2008: Phoqus Pharmaceuticals plc (AIM: PQS) ("Phoqus Pharmaceuticals"), the speciality pharmaceutical company,
has today published its report and accounts for the year ended 31 December 2007 and sent to shareholders notice of its Annual General
Meeting, which is scheduled for Thursday 12 June 2008 at 11:30am.
Electronic copies of the report and accounts are available to download on the investor relations section of the Phoqus Pharmaceuticals
website: www.phoqus.com. Hard copies are available by writing to the Company Secretary at the company's registered office: 10 Kings Hill
Avenue, West Malling, ME19 4PQ.
Enquiries:
Phoqus Pharmaceuticals plc
Suzanne Smith, Company Secretary Tel: 01732 870227
Nomura Code Securities Limited
Phil Walker Tel: 020 7776 1200
About Phoqus Pharmaceuticals
Phoqus Pharmaceuticals is a speciality pharmaceutical company that aims to develop differentiated products for use in high value,
specialist indications. Its first product candidate is Chronocort®, a novel physiological cortisol replacement therapy in development for
the treatment of patients with congenital adrenal hyperplasia and Addison's disease.
Further background on the Company can be found at www.phoqus.com.
Phoqus Pharmaceuticals plc
10 Kings Hill Avenue, Kings Hill, West Malling, Kent, ME19 4PQ
Telephone: +44 (0)1732 870227, Fax: +44 (0)1732 870228
Email: info@phoqus.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSSFSSUMSASEEI
1 Year Phoqus Chart |
1 Month Phoqus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
